

Wide disparities in attitudes and practices regarding Type II sphincter of Oddi dysfunction: a survey of expert U.S. endoscopists

Authors

Rabindra R. Watson¹, Jason Klapman², Srinadh Komanduri³, Janak N. Shah⁴, Sachin Wani⁵, Raman Muthusamy¹

Institutions

¹ UCLA Medical Center – Digestive Diseases, Los Angeles, California, USA

² Moffitt Cancer Center – Gastrointestinal Oncology, Tampa, Florida, USA

³ Northwestern University – Gastroenterology, Chicago, Illinois, USA

⁴ California Pacific Medical Center – Interventional Endoscopy, IES Lab, San Francisco, California, USA

⁵ University of Colorado and Veterans Affairs Medical Center – Gastroenterology, Aurora, Colorado, USA

submitted 8. February 2016
accepted after revision
13. June 2016

Bibliography

DOI <http://dx.doi.org/10.1055/s-0042-110789>
Published online: 10.8.2016
Endoscopy International Open 2016; 04: E941–E946
© Georg Thieme Verlag KG
Stuttgart · New York
E-ISSN 2196-9736

Corresponding author

Rabindra R. Watson, MD
UCLA Medical Center –
Digestive Diseases
200 Medical Plaza 330-33
Los Angeles
California 90095
USA
rabindrawatson@gmail.com

Background: Sphincter of Oddi manometry (SOM) is recommended in the evaluation of suspected Type II sphincter of Oddi dysfunction (SOD2), though its utility is uncertain. Little is known about the practice of expert endoscopists in the United States regarding SOD2.

Methods: An anonymous electronic survey was distributed to 128 expert biliary endoscopists identified from U.S. advanced endoscopy training programs.

Results: The response rate was 46.1% (59/128). Only 55.6% received training in SOM, and 49.2% currently perform SOM. For biliary SOD2, 33.3% routinely obtain SOM, 33.3% perform empiric sphincterotomy, and 26.3% perform single session endoscopic ultrasound/endoscopic retrograde cholangiopancreatography (EUS/ERCP). In contrast, an equal number (35.1%) favor SOM or single session EUS/ERCP for suspected acute idiopathic recurrent pancreatitis, while 19.3% would

perform empiric sphincterotomy. Those who perform SOM believe it to be important in predicting response to treatment compared with those who do not (71.8% vs 23.1%, $P=0.01$). Yet only 51.7% of this group performs SOM for suspected SOD2. Most (78.6%) believe that <50% of patients report improvement in symptoms after sphincterotomy. Common reasons for not obtaining SOM included unreliable results (50%), and procedure-related risks (39.3%). Most (59.3%) believe SOD2 is at least in part a functional disorder; only 3.7% felt SOD is a legitimate disorder of the sphincter of Oddi.

Conclusions: Our survey of U.S. expert endoscopists suggests that SOM is not routinely performed for SOD2 and concerns regarding its associated risks and validity persist. Most endoscopists believe SOD2 is at least in part a functional disorder that will not respond to sphincterotomy in the majority of cases.

Introduction

The term sphincter of Oddi dysfunction (SOD) is used to describe a syndrome of biliary type pain or acute idiopathic recurrent pancreatitis related to the function of the sphincter of Oddi [1]. The clinical diagnosis of SOD is based on a combination of clinical characteristics, serum enzyme levels, and imaging findings as outlined in the ROME III and Milwaukee classifications [1]. Most patients who demonstrate abnormalities in all three categories (Type I) will respond to endoscopic therapy with sphincterotomy thus obviating the role of sphincter of Oddi manometry (SOM) in this population [2]. In contrast, a recent randomized controlled trial found no benefit associated with SOM or sphincterotomy in patients with isolated pancreaticobiliary type pain (Type III), eliminating the need for endoscopic retrograde cholangiopancreatography (ERCP) in this population [3]. The optimal evaluation and therapy for

those patients with typical pain and only one other criterion for SOD (Type II), however, are less clear [1, 4].

SOM is currently recommended in the evaluation of suspected SOD Type II before endoscopic therapy based on the evidence that 60–94% of patients with a basal pressure >40 mmHg will respond to therapy [1, 5, 6]. Despite this recommendation, the use of SOM has been limited due to variable definitions of what constitutes an elevated sphincter pressure, perceived procedure-specific risks, and confounding factors attributable to the patient, endoscopist, equipment or choice of sedation [7–9]. As a result, alternative strategies including the use of empiric sphincterotomy and single session endoscopic ultrasound (EUS) with therapeutic ERCP based on structural causes of the patient's symptoms identified by EUS imaging have gained widespread acceptance [10–12]. However, there is a dearth of high quality data comparing these strategies [4–6].

License terms



In light of the limited available evidence in this patient population and the variety of management options, we sought to evaluate the current attitudes and practices with regard to the utility of SOM for suspected SOD2. To this end, we performed a survey study of expert biliary endoscopists in the United States.

Materials and methods

Survey instrument

A 23-question survey was developed to assess the current practice of expert endoscopists with respect to SOD Type II. Content validity was determined based on a review of relevant literature. Face validity was assessed by detailed interviews with expert biliary endoscopists at five tertiary care centers. The survey was divided into three sections. The first nine questions assessed demographics, training experience, and practice environment. The second section included questions pertaining to preferred treatment strategies of suspected biliary SOD2 and acute idiopathic recurrent pancreatitis, attitudes with regard to both the utility and risk associated with SOM, and attitudes with regard to the diagnosis of SOD itself. The final section contained two additional questions to assess the current state of SOM training in the United States (see Appendix).

Participants and survey distribution

An invitation to participate in the online survey study was delivered by electronic message to 128 pancreaticobiliary endoscopists identified from advanced endoscopy training programs in the United States listed in the ASGE directory. A second email invitation was then delivered 2 weeks later to maximize response rates. Consent to participate was derived from voluntary completion of the survey. A direct Web link to the survey instrument was provided. No personal identifying information was collected and no incentive for survey completion was provided. Responses were collected using an online survey tool (SurveyMonkey, Palo Alto, California, United States).

Data management and statistical analysis

Categorical variables were expressed using percentages. The standard χ^2 test and Fisher's exact test were used for comparisons between groups. Results were calculated per question completed independent of survey completion. All *P* tests were two-sided, and a *P* value of <0.05 was considered statistically significant. Approval from the institutional review board of UCLA Medical Center was obtained. Statistical analysis was performed using statistical software JMP Pro 11 (SAS, Cary, North Carolina, United States).

Results

Study population characteristics

In total, 59 of 128 (46.1%) subjects completed the survey. Most respondents practice in a tertiary care facility (94.9%) and completed a third tier advanced endoscopy fellowship (71.2%), though only 56.9% of respondents received training in SOM (Table 1). While the majority currently perform ERCP (94.9%) and EUS (79.7%) in their practice, only 49.2% perform SOM. The vast majority of respondents reported a typical caseload of three or fewer cases of suspected SOD encountered per month. For those who do not perform SOM (50.8%), SOM is readily available

Table 1 Respondent demographics.

Number of respondents	59
Years in practice (mean \pm SD)	14.1 \pm 9.85
Completed third tier fellowship, no. (%)	42 (71.2)
Currently perform ERCP, no. (%)	56 (94.9)
Currently perform EUS, no. (%)	47 (79.7)
Currently perform SOM, no. (%)	29 (49.2)
Availability of SOM, no. (%)	
Yes, within practice group	14 (48.3)
Yes, outside practice group	10 (34.8)
No	5 (17.2)
Received training in SOM, no. (%)	33 (56.9)
Offer training in SOM, no. (%)	29 (55.6)
Believe trainees 'rarely' or 'never' request training in SOM, no. (%)	32 (64)

ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; SOM, sphincter of Oddi manometry.

Table 2 Preferred management strategy for suspected SOD Type II/acute idiopathic recurrent pancreatitis.

Biliary	
SOM, no. (%)	19 (33.3)
Empiric sphincterotomy, no. (%)	19 (33.3)
EUS/ERCP, no. (%)	15 (26.3)
Acute idiopathic recurrent pancreatitis	
SOM, no. (%)	20 (35.1)
Empiric sphincterotomy, no. (%)	11 (19.3)
EUS/ERCP, no. (%)	20 (35.1)

ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; SOM, sphincter of Oddi manometry.

either within their practice group (48.3%) or via outside referral (34.5%).

Practice patterns

Despite the availability of SOM, an equivalent number of respondents (33.3%) would perform empiric sphincterotomy versus SOM for the management of suspected biliary SOD2 (Table 2). Moreover, an additional 26.3% would perform single session EUS \pm sphincterotomy based on EUS findings (duct dilation, stones present) as their initial approach. In contrast, an equal number of respondents (35.1%) would perform SOM or single session EUS/ERCP in the management of suspected acute idiopathic recurrent pancreatitis. Only 19.3% would perform empiric sphincterotomy in this situation. Notably, when restricting analysis to those respondents who routinely perform SOM, only 51.7% would do so as part of their endoscopic evaluation for suspected biliary or pancreatic SOD2.

Attitudes and training

Most respondents (85.5%) believe that patients undergoing SOM for suspected SOD2 will ultimately undergo sphincterotomy. However, the vast majority feel that <50% of patients would report improvement in symptoms. In addition, half of respondents cite a lack of reliable results as the reason they do not obtain SOM, while an additional 39.3% cite procedure-related risks (Fig. 1). Overall, endoscopists believe duct dilation (40.7%), enzyme elevation (61%), and typical symptoms (50.1%) are "very important" or "extremely important" in predicting response to treatment. Interestingly, a wide disparity in the perceived importance of SOM pressures was observed, with 37.7% of respondents believ-




Fig. 1 What are your reasons for not obtaining SOM?*

* Respondents may select more than one response. SOM: sphincter of Oddi manometry.

ing them to be “not important” or “not very important”, while an equal percentage found them “very important” or “extremely important”. A significantly greater percentage of those who perform SOM believe them “very important” or “extremely important” compared with those who do not (71.8 vs 23.1 %, $P=0.01$). No significant difference was seen in the perceived value of duct dilation, enzyme elevation or symptoms between these groups (Table 3).

Regarding the diagnosis of SOD2, half of respondents believe SOD to be at least in part a functional gastrointestinal disorder, and only 3.7% of those surveyed believe SOD to be a legitimate pathologic disorder of the sphincter of Oddi (Fig. 2). Of the 52 respondents who reported offering training in advanced endoscopy, only 55.8% currently provide training in SOM. In addition, these respondents report that 64% of trainees “rarely” or “never” request training in SOM.

Procedural risks and adverse events

When discussing the procedure-specific risks of SOM with patients, most endoscopists quote a rate of complications of >15%. Accordingly, 31% of respondents who perform SOM routinely admit patients following this procedure, and the majority (84.7%) of all respondents will place pancreatic duct stents following endoscopic intervention.

Discussion

This survey study of expert pancreaticobiliary endoscopists demonstrates substantial heterogeneity in the diagnostic approach to suspected SOD2 in the United States. Despite the longstanding recommendation for the use of SOM as suggested in the Milwaukee and Rome III guidelines, the majority of respondents do not adhere to this protocol. Endoscopists are instead relying on either empiric sphincterotomy or EUS-directed ERCP in lieu of SOM. The reasons behind the varied approaches are multifactorial, though our data provide some novel insight into the opinions and practices of this cohort.

It is evident that endoscopists remain skeptical regarding the utility of SOM and its impact on management decisions. This skepticism is reflected in the beliefs held by half of respondents that the data supplied by manometry is unreliable, and that most believe that patients will ultimately undergo sphincterotomy regardless of SOM results. Furthermore, as half of the respondents believe SOD to be at least in part a functional disorder, these endoscopists may opt to avoid this diagnostic test. Indeed such uncertainty regarding the role of SOM in suspected SOD has been well documented in the existing literature, with SOM failing to consistently

Table 3 Variables believed to be ‘important’ or ‘extremely important’ in predicting response to treatment.

Variable	Perform SOM, no. (%)	Do not perform SOM, no. (%)	P value
Duct dilation	11 (41)	13 (48.1)	0.483*
Enzyme elevation	18 (66.7)	18 (66.7)	1*
Symptoms	17 (62)	14 (51.9)	0.65*
SOM pressure	14 (71.8)	6 (23.1)	0.01*

SOM, sphincter of Oddi manometry.

* Fisher’s Exact Test.




Fig. 2 Which best describes your opinion regarding SOD2? SOD: sphincter of Oddi dysfunction.

tently predict response to sphincterotomy across three randomized trials and several cohort studies [4–6, 13].

Our results also demonstrate that those who perform SOM place significantly greater importance on SOM data in predicting symptom response to sphincterotomy than those who do not. However, it is notable that only approximately half of those who perform SOM would actually use the procedure in the evaluation of SOD2. Whether these physicians perform single session EUS/ERCP or empiric sphincterotomy in this situation was not assessed, though the apparent disparity between belief and clinical practice emphasizes the uncertain role of SOM in this situation. While it is evident that an elevated risk of pancreatitis is associated with performance of ERCP in patients with SOD, it is increasingly recognized that this risk exists irrespective of the procedures performed, including SOM [13–16]. Despite this evidence to the contrary, nearly 40% of endoscopists surveyed continue to avoid SOM due to perceived procedure-specific risk. This suggests a persistent bias against SOM-related risks, even amongst expert U.S. endoscopists at tertiary care facilities, and may explain the frequent use of EUS as an alternative diagnostic test.

Unsurprisingly, these perceived limitations of SOM are reflected in current advanced endoscopy training as only approximately half of surveyed expert endoscopists have received training in SOM and currently offer training in this procedure. Furthermore, as most find that trainees do not actively seek training in this technique, it is plausible that dissemination of this procedure will decline in the United States in the near future, further limiting its applicability in clinical practice.

This study has limitations inherent to survey-based investigations, including recall and selection bias. While an anonymous survey will mitigate reporting bias associated with voluntary reporting of outcomes, this remains a possible limitation. As this investigation was directed towards U.S. expert pancreaticobiliary endoscopists at tertiary care facilities, our results may not be generalizable to the endoscopic community at large. However, as the use of SOM is generally limited to referral centers, we sought to specifically capture the practices of this physician group.

In conclusion, despite previous recommendations for the use of SOM in the evaluation of SOD2, our study suggests that SOM is not routinely performed in clinical practice, as many experts question its validity and continue to harbor reservations with regard to the associated risks of the test itself. Given the current disparity in practice patterns, reliance on EUS-directed ERCP, and lack of high quality evidence to guide management of suspected SOD2, further prospective studies delineating the optimal evaluation and management of this controversial diagnosis are needed.

Competing interests: None

References

- Behar J, Corazziari E, Guelrud M et al. Functional gallbladder and sphincter of oddi disorders. *Gastroenterology* 2006; 130: 1498–1509
- Thatcher BS, Sivak MV, Tedesco FJ et al. Endoscopic sphincterotomy for suspected dysfunction of the sphincter of Oddi. *Gastrointest Endosc* 1987; 33: 91–95
- Cotton PB, Durkalski V, Romagnuolo J et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. *JAMA* 2014; 311: 2101–2109
- Toouli J, Roberts-Thomson IC, Kellow J et al. Manometry based randomised trial of endoscopic sphincterotomy for sphincter of Oddi dysfunction. *Gut* 2000; 46: 98–102
- Geenen JE, Hogan WJ, Dodds WJ et al. The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. *NEJM* 1989; 320: 82–87
- Sherman S, Lehman G, Jamindar P et al. Efficacy of endoscopic sphincterotomy and surgical sphincteroplasty for patients with sphincter of Oddi dysfunction (SOD): randomized, controlled study. *Gastrointest Endosc* 1994; 40: P125
- Guelrud M, Mendoza S, Rossiter G et al. Sphincter of Oddi manometry in healthy volunteers. *Dig Dis Sci* 1990; 35: 38–46
- Maldonado ME, Brady PG, Mamel JJ et al. Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM). *Am J Gastroenterol* 1999; 94: 387–390
- Smithline A, Hawes R, Lehman G. Sphincter of Oddi manometry: inter-observer variability. *Gastrointest Endosc* 1993; 39: 486–491
- Coyle WJ, Pineau BC, Tarnasky PR et al. Evaluation of unexplained acute and acute recurrent pancreatitis using endoscopic retrograde cholangiopancreatography, sphincter of Oddi manometry and endoscopic ultrasound. *Endoscopy* 2002; 34: 617–623
- Arguedas MR, Linder JD, Wilcox CM. Suspected sphincter of Oddi dysfunction type II: empirical biliary sphincterotomy or manometry-guided therapy? *Endoscopy* 2004; 36: 174–178
- Khashab MA, Watkins JL, McHenry L et al. Frequency of sphincter of Oddi dysfunction in patients with previously normal sphincter of Oddi manometry studies. *Endoscopy* 2010; 42: 369–374
- Petersen BT. An evidence-based review of sphincter of Oddi dysfunction: part I, presentations with “objective” biliary findings (types I and II). *Gastrointest Endosc* 2004; 59: 525–534
- Sheehan SJ, Lee JH, Wells CK et al. Serum amylase, pancreatic stents, and pancreatitis after sphincter of Oddi manometry. *Gastrointest Endosc* 2005; 62: 260–265
- Tarnasky PR, Palesch YY, Cunningham JT et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. *Gastroenterology* 1998; 115: 1518–1524
- Singh P, Gurudu SR, Davidoff S et al. Sphincter of Oddi manometry does not predispose to post-ERCP acute pancreatitis. *Gastrointest Endosc* 2004; 59: 499–505

Appendix

1. What is the setting of your practice?
 - Tertiary referral center
 - Multispeciality Group
 - HMO
 - Solo Practice
2. Where did you receive your gastroenterology fellowship training?
 Program Name: _____
 City, State: _____
3. If applicable, where did you receive your third tier (4th year) advanced endoscopy fellowship?
 Program Name: _____
 City, State: _____
4. Please check all that apply to your **training**:
 If yes, number of procedures
 - Training in EUS during 3-year fellowship _____
 - Training in EUS during dedicated 4th year _____
 - Training in ERCP during 3-year fellowship _____
 - Training in ERCP during dedicated 4th year _____
 - Training in sphincter of Oddi manometry _____
5. How many years have you been in practice _____
6. Please check all that apply to your **current practice**:
 - I perform EUS
 - I perform ERCP
 - I perform sphincter of Oddi manometry (SOM)
 - None of the above
7. If you perform ERCP, on average, how many ERCP's do you perform per year?
 - I do not perform ERCP
 - 0 – 100
 - 101 – 250
 - 251 – 500
 - 501 – 1000
 - >1000
8. On average, how many patients with suspected sphincter of Oddi dysfunction (SOD) do you evaluate per month?
 - 0 – 3
 - 4 – 7
 - 8 – 12
 - 12+
9. If you do not perform ERCP, is sphincter of Oddi manometry (SOM) readily accessible for the diagnostic work up of patients with suspected SOD?
 - Yes, within my practice group
 - Yes, outside referral
 - No
10. What is your typical practice in evaluating cases of suspected TYPE II BILIARY SOD?
 - Refer Patient
 - ERCP with Sphincter of Oddi Manometry ± subsequent endotherapy as indicated
 - Empiric sphincterotomy
 - EUS ± ERCP with biliary sphincterotomy based on EUS findings (duct dilation, stones, etc.)
11. What is your typical practice in evaluating cases of suspected TYPE II PANCREATIC SOD?
 - Refer Patient
 - ERCP with Sphincter of Oddi Manometry ± subsequent endotherapy as indicated
 - Empiric sphincterotomy
 - EUS ± ERCP with biliary sphincterotomy based on EUS findings (duct dilation, stones, etc.)
12. What is your quoted rate of complications when discussing SOM with patients?
 - 0 – 5%
 - 6 – 10%
 - 11 – 15%
 - 16 – 20%
 - >20%
13. In your practice do you (Check all that apply):
 - Routinely admit patients after SOM
 - Routinely admit patients after ERCP with sphincterotomy
 - I do not routinely admit patients after SOM or ERCP with sphincterotomy
14. Do you routinely place pancreatic duct stents following ERCP in patients with suspected SOD? (Check all that apply):
 - Yes, after biliary SOM
 - Yes, after pancreatic SOM
 - Yes, after ERCP with biliary sphincterotomy
 - Yes, after ERCP with pancreatic sphincterotomy
 - No, I do not routinely place pancreatic duct stents after SOM or sphincterotomy
15. In your opinion, what percentage of patients with suspected biliary or pancreatic type II SOD ultimately undergo sphincterotomy following SOM?
 - 0 – 25%
 - 26 – 50%
 - 51 – 75%
 - 76 – 100%
16. In your opinion, what percentage of patients report a subjective improvement of symptoms after **biliary** sphincterotomy for treatment of biliary SOD type 2?
 - 0 – 25%
 - 26 – 50%
 - 51 – 75%
 - 76 – 100%
17. In your opinion, what percentage of patients report a subjective improvement of symptoms after **pancreatic** sphincterotomy for treatment of pancreatic SOD type 2?
 - 0 – 25%
 - 26 – 50%
 - 51 – 75%
 - 76 – 100%

18. If you do not routinely obtain SOM in the evaluation of suspected SOD2, what are your reasons? (check all that apply):
- Cost
 - Procedure-related risks (Post-ERCP Pancreatitis)
 - Lack of reliable results (false positive and false negative results)
 - Lack of availability
 - Unfamiliarity with the procedure

19. How important are each of the following in predicting response to treatment of SOD type 2?

Duct dilation

Extremely Important
 Very Important
 Somewhat Important
 Not Very Important
 Not Important

Enzyme elevation

Extremely Important
 Very Important
 Somewhat Important
 Not Very Important
 Not Important

History (symptoms)

Extremely Important
 Very Important
 Somewhat Important
 Not Very Important
 Not Important

SOM pressures

Extremely Important
 Very Important
 Somewhat Important
 Not Very Important
 Not Important

For the following case presentation, please choose your next step in management:

20. A 45-year-old otherwise healthy woman presents with intermittent right upper quadrant pain exacerbated by fatty meals, normal serum liver and pancreatic enzyme levels, and a dilated common bile duct of 14 mm and normal gallbladder on trans-abdominal ultrasound.
- Perform ERCP with biliary sphincterotomy
 - Perform single session EUS ± ERCP with biliary sphincterotomy if EUS corroborates duct dilation
 - Perform ERCP with SOM and possible sphincterotomy as dictated by manometry
 - Obtain MRCP and if abnormal, perform ERCP with sphincterotomy
 - Trial of anti-spasmodics
21. Which best describes your opinion regarding sphincter of Oddi dysfunction?
- A manifestation of a functional gastrointestinal disorder
 - A controversial disease process with unclear pathologic mechanisms
 - A syndrome encompassing mechanical dysfunction of the sphincter of Oddi as well as a functional GI disorder
 - A legitimate disease process with unclear pathologic mechanisms
 - Not an organic disease
22. Do you offer training in SOM to advanced endoscopy fellows?
- Yes
 - No
23. How often to advanced endoscopy fellows request training in SOM?
- Never Rarely Sometimes Often Always